EXCLUSIVE: Leadership race shows how diversity is the 'new normal' in public life
If we want an inclusive Britain, every party that aspires to govern our country should commit to meeting a simple ‘One Nation' test, says Katwala.
By Sunder Katwala Jul 11, 2022
Prime minister Boris Johnson certainly went down fighting. Sajid Javid and Rishi Sunak had decided that enough was enough, resigning last week from the Cabinet over Downing Street’s inability to tell the truth. Fifty ministerial resignations later, the refusal of the prime minister to accept that the game was up descended into Whitehall farce. The newly appointed chancellor, Nadhim Zahawi, publicly declared his lack of confidence in the Prime Minister while staying in post. There were three education secretaries in three days. Those futile final twelve hours of delusion and denial were a mere cameo by the standards of Donald Trump’s violent insurgency in America, but without precedent in a century of British political transitions.
This meltdown has damaged the routine business of government during the two-month transition, especially since junior ministers who had resigned during the upheavals were not then offered the chance to return to their old jobs once the prime minister recognised the inevitable. The flagship Levelling Up department saw its ministerial team decimated. The Northern Ireland Secretary’s resignation was accepted, even though the prime minister was already planning his resignation speech that morning.
Rishi Sunak's leadership campaign has the optimism about an inclusive patriotism that can unite the country (Photo by Hollie Adams/Getty Images)
The leadership contest that now follows offers a powerful illustration of how ethnic diversity has become a “new normal” in British public life. To have six or seven ethnic minority candidates among the dozen leadership contenders is unprecedented – for any political party in a major western democracy. The Conservatives had their first Asian MP back in 1895, but they had to wait a century to 1992 for their second, and beyond the millennium for their third in 2005. It is easy to forget how rapid this shift has been: no British Asian had ever been in Cabinet until after 2010 and no Asian woman had ever been elected to the Commons until 2010 either.
Rishi Sunak launched his leadership campaign with his family story of the positive contribution of immigration to Britain and his optimism about an inclusive patriotism that can unite the country. Some commentators have challenged that as jarring with the government’s approach to immigration.
The ethnic minority candidates – like their white British counterparts – have different priorities and policies (Photo by Chris J Ratcliffe/Getty Images)
After ending freedom of movement from the EU, Johnson broke with Theresa May’s agenda, offering a more liberal approach to non-EU immigration. Controlling immigration after Brexit has not meant reducing the overall numbers. Immigration from India, Nigeria and Hong Kong is rising. The Hong Kong visa offer has particularly strong support. It seems unlikely that many leadership candidates will significantly reverse this liberal approach to student and work migration overall.
Asylum is a much more polarising issue. Priti Patel’s Rwanda plan is not popular with the general public, but picking fights with lawyers and bishops has helped to polarise attitudes along party lines. So if the Rwanda plan is prominent in this leadership contest, candidates may feel pressed to deepen their commitment to it. The candidates perceived as being on the left of the field – Jeremy Hunt and Tom Tugendhat – were quick to endorse the plan. Yet several candidates are aware of the legal and practical difficulties in making the plan work. A new leader may yet reconsider it over time, especially if critics of the Rwanda deal can demonstrate that they have a viable alternative to address dangerous Channel crossings.
Sunder Katwala (photo by Andrew Aitchison)
In a leadership contest, the candidates will focus on the party audiences, of MPs and party members, first. The ethnic minority candidates – like their white British counterparts – have different priorities and policies. Sunak and Javid, like Penny Mordaunt, emphasise bridging themes, being intuitively sceptical about identity clashes as an electoral strategy. Kemi Badenoch, Patel and Suella Braverman will argue for a stronger line about how Conservatives should contest arguments about identity and culture with the left.
Sunak might have won this leadership contest at a canter if it had been held six months ago, having been the most popular minister through the pandemic. His bruising spring – with the rather unfair fixed penalty notice fine, significant pressure over his tax affairs and furore over the non-dom status of his wife – mean this contest will be a wide-open race, though the bookmakers make Sunak the early favourite. Sunak’s role in ending the Johnson government will bring him new enemies as well as allies. Whoever wins or loses the contest, the arguments about taxation and spending, and how to appeal to the voters, will matter more than ethnicity or faith.
If we want an inclusive Britain, every party that aspires to govern our country should commit to meeting a simple ‘One Nation’ test: no citizen should feel there is a tension between supporting that party and their faith or ethnic background, if they share its broad vision and values. The Conservative party’s commitment to diversity at the top shows significant progress on representation. But ethnic minority faces in high places are not enough without the vision and values for the country too.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.